Literature DB >> 30531852

Preventing immune-complex-mediated disease.

Nicholas J Bernard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30531852     DOI： 10.1038/s41584-018-0137-y

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Authors:  Margreet Kloppenburg; Charles Peterfy; Ida K Haugen; Féline Kroon; Su Chen; Li Wang; Wei Liu; Gwen Levy; Roy M Fleischmann; Francis Berenbaum; Désirée van der Heijde; Prashant Bansal; Ruth Wittoek; Sheng Feng; Yuni Fang; Mary Saltarelli; Jeroen K Medema; Marc C Levesque
Journal:  Ann Rheum Dis       Date:  2018-12-14       Impact factor: 19.103
  1 in total
  1 in total

1.  Targeted and activatable nanosystem for fluorescent and optoacoustic imaging of immune-mediated inflammatory diseases and therapy via inhibiting NF-κB/NLRP3 pathways.

Authors:  Lihe Sun; Juan Ouyang; Zhuo Zeng; Cheng Zeng; Yunqing Ma; Fang Zeng; Shuizhu Wu
Journal:  Bioact Mater       Date:  2021-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.